Parathyroid Hormone-Related Protein (PTHrP) Accelerates Soluble RANKL Signals for Downregulation of Osteogenesis of Bone Mesenchymal Stem Cells
Open Access
- 12 June 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (6), 836
- https://doi.org/10.3390/jcm8060836
Abstract
A recent study reported the expression of receptor activator of nuclear factor-κB (RANK) in mesenchymal stem cells (MSCs) surface that negatively regulates osteogenesis of MSCs. Empirical evidence from the previous study confirmed the role of parathyroid hormone-related protein (PTHrP) in osteoblastogenesis. However, it is necessary to understand the paracrine role of PTHrP and RANKL for osteogenesis in order to explore the hidden secrets in bone biology. Considering the above concept, paracrine cues of soluble-receptor activator of nuclear factor-κB ligand (sRANKL) and PTHrP in osteogenic differentiation of MSCs were investigated. Our results confirmed that sRANKL increased the expression of surface-RANK in MSCs at the earlier stage of osteogenesis, which was downregulated later in differentiated MSCs. In contrast, RANKL expression was low at the earlier stage of MSCs proliferation and high at the differentiation stage of MSCs, which may play a fundamental role in osteoclast formation. sRANKL downregulated osteogenesis of MSCs by decreasing progressive ankylosis (ANK) protein expression while PTHrP upregulated the osteogenic exploitive effect of sRANKL. Interestingly, when they were co-cultured with MSCs, T-lymphocytes expressed high membrane-RANKL levels that contribute to osteogenesis inhibition during MSC differentiation. Thus, our results disclose that sRANKL treatment downregulates osteogenesis of MSCs by increasing RANK expression at the earlier stage of differentiation and by inhibiting ANK. Further, we demonstrated that PTHrP accelerated the downregulating osteogenic effect of sRANKL.Keywords
Funding Information
- National High Technology Research and Development Program of China (2011AA09070109, 15410722500)
- National Natural Science Foundation of China (81750110548)
This publication has 34 references indexed in Scilit:
- In Vitro Mesenchymal Trilineage Differentiation and Extracellular Matrix Production by Adipose and Bone Marrow Derived Adult Equine Multipotent Stromal Cells on a Collagen ScaffoldStem Cell Reviews and Reports, 2013
- Osteocyte RANKL: New insights into the control of bone remodelingJournal of Bone and Mineral Research, 2012
- Matrix-embedded cells control osteoclast formationNature Medicine, 2011
- Progressive ankylosis protein (ANK) in osteoblasts and osteoclasts controls bone formation and bone remodelingJournal of Bone and Mineral Research, 2010
- PTHrP prevents chondrocyte premature hypertrophy by inducing cyclin-D1-dependent Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal degradationJournal of Cell Science, 2009
- B and T Lymphocytes Are the Primary Sources of RANKL in the Bone Resorptive Lesion of Periodontal DiseaseThe American Journal of Pathology, 2006
- Receptor Activator of NF-κB Ligand (RANKL) Activates TAK1 Mitogen-Activated Protein Kinase Kinase Kinase through a Signaling Complex Containing RANK, TAB2, and TRAF6Molecular and Cellular Biology, 2002
- Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)Journal of Biological Chemistry, 2000
- Parathyroid Hormone-Related Protein-(1-36) Is Biologically Active When Administered Subcutaneously to HumansJournal of Clinical Endocrinology & Metabolism, 1997
- PTH: A future role in the management of osteoporosis?Journal of Bone and Mineral Research, 1996